4-甲硫基安非他明 | 14116-06-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲硫基安非他明
• 英文名称: 4-methylthioamphetamine
• 英文别名: 4-MTA；1-(4-methylsulfanylphenyl)propan-2-amine
• CAS: 14116-06-4
• 化学式: C₁₀H₁₅NS
• 分子量: 181.302
• InChiKey: OLEWMKVPSUCNLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-甲硫基安非他明 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-Amino-1-<4-methylsulfon-phenyl>-propan
  参考文献：
  名称：

  Synthesis and serotonin transporter activity of sulphur-substituted α-alkyl phenethylamines as a new class of anticancer agents

  摘要：

  The discovery that some serotonin reuptake transporter (SERT) ligands have the potential to act as pro-apoptotic agents in the treatment of cancer adds greatly to their diverse pharmacological application. 4-Methylthioamphetamine (MTA) is a selective ligand for SERT over other monoamine transporters. In this study, a novel library of structurally diverse 4-MTA analogues were synthesised with or without N-alkyl and/or C-alpha methyl or ethyl groups so that their potential SERT-dependent antiproliferative activity could be assessed.Many of the compounds displayed SERT-binding activity as well as cytotoxic activity. While there was no direct correlation between these two effects, a number of derivatives displayed anti-tumour effects in lymphoma, leukaemia and breast cancer cell lines, showing further potential to be developed as possible chemotherapeutic agents. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.07.027
• 作为产物：
  描述：

  1-(4-methylthiophenyl)-2-nitro-1-propene 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以80%的产率得到4-甲硫基安非他明
  参考文献：
  名称：

  Synthesis and serotonin transporter activity of sulphur-substituted α-alkyl phenethylamines as a new class of anticancer agents

  摘要：

  The discovery that some serotonin reuptake transporter (SERT) ligands have the potential to act as pro-apoptotic agents in the treatment of cancer adds greatly to their diverse pharmacological application. 4-Methylthioamphetamine (MTA) is a selective ligand for SERT over other monoamine transporters. In this study, a novel library of structurally diverse 4-MTA analogues were synthesised with or without N-alkyl and/or C-alpha methyl or ethyl groups so that their potential SERT-dependent antiproliferative activity could be assessed.Many of the compounds displayed SERT-binding activity as well as cytotoxic activity. While there was no direct correlation between these two effects, a number of derivatives displayed anti-tumour effects in lymphoma, leukaemia and breast cancer cell lines, showing further potential to be developed as possible chemotherapeutic agents. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.07.027

文献信息

• [EN] SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1<br/>[FR] AGONISTES À PETITES MOLÉCULES DE RÉCEPTEUR DE NEUROTENSINE 1
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2014100501A1

  公开（公告）日：2014-06-26

  Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

  提供的是小分子神经降压素受体激动剂，包含这些化合物的组合物，以及使用这些化合物和包含这些化合物的组合物的方法。
• [EN] HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF<br/>[FR] COMPOSÉS D'HÉTÉROARYLAMINE POUR MODULER LA VOIE HEDGEHOG ET PROCÉDÉ DE PRÉPARATION ET UTILISATIONS DE CEUX-CI
  申请人：DEV CT BIOTECHNOLOGY

  公开号：WO2018098250A1

  公开（公告）日：2018-05-31

  The present invention provides a compound of formula (I) wherein X, Y, Z1, Z2, R1, R2, A, B, p and q are as disclosed in the specification. A pharmaceutical composition and a method for modulating the Hedgehog pathway are also provided. The present invention further provides a process for preparing the compound.

  本发明提供了一种化合物，其化学式为（I），其中X、Y、Z1、Z2、R1、R2、A、B、p和q如规范中所披露。还提供了一种调节Hedgehog通路的药物组合物和方法。本发明还提供了一种制备该化合物的方法。
• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。
• Determination of the chiral status of different novel psychoactive substance classes by capillary electrophoresis and β‐cyclodextrin derivatives
  作者：Johannes S. Hägele、Eva‐Maria Hubner、Martin G. Schmid

  DOI：10.1002/chir.23268

  日期：2020.9

  aforementioned compound classes. Enantioresolution was achieved by simply adding native β‐cyclodextrin, acetyl‐β‐cyclodextrin, 2‐hydroxypropyl‐β‐cyclodextrin, or carboxymethyl‐β‐cyclodextrin as chiral selector additives to the background electrolyte. Fifty‐one chiral NPS served as analytes mainly purchased from online vendors via the Internet. Using 10 mM of the aforementioned β‐cyclodextrins in a 10 mM

  除了滥用众所周知的非法药物外，消费者还发现了新的合成化合物，它们具有相似的作用，但化学结构发生了微小变化。最初，创建这些所谓的新型精神活性物质（NPS）是为了规避因滥用毒品而引起的起诉法。在过去的十年中，此类化合物世代相传，最流行的化合物是合成的甲基吡啶酮衍生物，称为甲氧麻黄酮。卡西酮在结构上与苯丙胺有关；迄今为止，已经合成了120多种全新的衍生物，并通过Internet进行了交易。卡西酮具有手性中心。然而，关于其对映体的药理学知之甚少。但是，NPS还包含其他手性化合物，例如苯丙胺衍生物，氯胺酮，2-（氨基丙基）苯并呋喃，和吩啶。在我们的项目继续中，以前介绍的一种廉价，易于执行的手性毛细管电泳区分离卡西酮的方法已扩展到上述化合物类别。通过将天然β-环糊精，乙酰基-β-环糊精，2-羟丙基-β-环糊精或羧甲基-β-环糊精作为手性选择剂添加到背景电解质中，即可实现对映体拆分。51个手性NPS用作